MRI-measured periprostatic adipose tissue volume as a prognostic predictor in prostate cancer patients undergoing laparoscopic radical prostatectomy

References

• PJ P, Bazelier MT, Leufkens HG, et al. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. Diabetes Care. 2015;38:495–7.
   PubMed Web of Science ®Google Scholar
• Kokts-Porietis RL, McNeil J, Morielli AR, et al. Prospective cohort study of pre- and post-diagnosis obesity and endometrial cancer survival. J Natl Cancer Inst. 2021;114:409–418.
   Google Scholar
• Long E, IL B. The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol. 2014;7:247–268.
   PubMed Web of Science ®Google Scholar
• Rodriguez C, Freedland SJ, Deka A, et al. Body mass index, weight change, and risk of prostate cancer in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:63–69.
   PubMed Web of Science ®Google Scholar
• Kelly SP, Graubard BI, Andreotti G, et al. Prediagnostic body mass index trajectories in relation to prostate cancer incidence and mortality in the PLCO cancer screening trial. J Natl Cancer Inst. 2017;109:djw225.
   PubMedGoogle Scholar
• Bai PD, Hu MB, Xu H, et al. Body mass index is associated with higher Gleason score and biochemical recurrence risk following radical prostatectomy in Chinese men: a retrospective cohort study and meta-analysis. World J Surg Oncol. 2015;13:311.
   PubMed Web of Science ®Google Scholar
• Pfitzenmaier J, Pritsch M, Haferkamp A, et al. Is the body mass index a predictor of adverse outcome in prostate cancer after radical prostatectomy in a mid-European study population? BJU Int. 2009;103:877–882.
   PubMed Web of Science ®Google Scholar
• Häggström C, Stocks T, Ulmert D, et al. Prospective study on metabolic factors and risk of prostate cancer. Cancer. 2012;118:6199–6206.
   PubMed Web of Science ®Google Scholar
• Bassett JK, Severi G, Baglietto L, et al. Weight change and prostate cancer incidence and mortality. Int J Cancer. 2012;131:1711–1719.
   PubMed Web of Science ®Google Scholar
• Toren P, Venkateswaran V. Periprostatic adipose tissue and prostate cancer progression: new insights into the tumor microenvironment. Clin Genitourin Cancer. 2014;12:21–26.
   PubMed Web of Science ®Google Scholar
• Bhindi B, Trottier G, Elharram M, et al. Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int. 2012;110:980–986.
   PubMed Web of Science ®Google Scholar
• van Roermund JG, Hinnen KA, Tolman CJ, et al. Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJU Int. 2011;107:1775–1779.
   PubMed Web of Science ®Google Scholar
• Woo S, Cho JY, Kim SY, et al. Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer. AJR Am J Roentgenol. 2015;204:W43–7.
   PubMed Web of Science ®Google Scholar
• Iemura Y, Hori S, Tatsumi Y, et al. Periprostatic fat thickness quantified by preoperative magnetic resonance imaging is an independent risk factor for upstaging from cT1/2 to pT3 in robot-assisted radical prostatectomy. Int J Urol. 2020;27:1144–1149.
   PubMed Web of Science ®Google Scholar
• Gregg JR, Surasi DS, Childs A, et al. The association of periprostatic fat and grade group progression in men with localized prostate cancer on active surveillance. J Urol. 2021;205(1):122–128. DOI:10.1097/JU.0000000000001321
   PubMed Web of Science ®Google Scholar
• Salji M, Hendry J, Patel A, et al. Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer. Eur Urol Focus. 2018;4(6):858–866.
   PubMedGoogle Scholar
• Huang H, Chen S, Li W, et al. Periprostatic fat thickness on MRI is an independent predictor of time to castration-resistant prostate cancer in Chinese patients with newly diagnosed prostate cancer treated with androgen deprivation therapy. Clin Genitourin Cancer. 2019;17(5):e1036–1047.
   PubMed Web of Science ®Google Scholar
• Sasaki T, Sugino Y, Kato M, et al. Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naïve men with advanced prostate cancer. Int J Clin Oncol. 2020;25(2):370–376.
   PubMed Web of Science ®Google Scholar
• Di Bella CM, Howard LE, Oyekunle T, et al. Abdominal and pelvic adipose tissue distribution and risk of prostate cancer recurrence after radiation therapy. Prostate. 2020;80(14):1244–1252. DOI:10.1002/pros.24054
   PubMed Web of Science ®Google Scholar
• Tan WP, Lin C, Chen M, et al. Periprostatic fat: a risk factor for prostate cancer? Urology. 2016;98:107–112.
   PubMed Web of Science ®Google Scholar
• Ishidoya S, Endoh M, Nakagawa H, et al. Novel anatomical findings of the prostatic gland and the surrounding capsular structures in the normal prostate. Tohoku J Exp Med. 2007;1:55–62.
   Google Scholar
• Nassar ZD, Aref AT, Miladinovic D, et al. Peri-prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU Int. 2018;121:9–21.
   PubMed Web of Science ®Google Scholar
• Gucalp A, Iyengar NM, Zhou XK, et al. Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis. 2017;20:418–423.
   PubMed Web of Science ®Google Scholar
• Roumiguié M, Estève D, Manceau C, et al. Periprostatic adipose tissue displays a chronic hypoxic state that limits its expandability. Am J Pathol. 2022;192:926–942.
   PubMed Web of Science ®Google Scholar
• Laurent V, Guérard A, Mazerolles C, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7:10230.
   PubMed Web of Science ®Google Scholar
• Dahran N, Szewczyk-Bieda M, Wei C, et al. Normalized periprostatic fat MRI measurements can predict prostate cancer aggressiveness in men undergoing radical prostatectomy for clinically localised disease. Sci Rep. 2017;7(1):4630.
   PubMedGoogle Scholar